Prognostic impact of CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study.
Adult
Aged
Biomarkers, Tumor
Carcinoma, Mucoepidermoid
/ diagnosis
Female
Humans
In Situ Hybridization, Fluorescence
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Oncogene Proteins, Fusion
/ genetics
Prognosis
Retrospective Studies
Salivary Gland Neoplasms
/ diagnosis
Trans-Activators
/ genetics
Transcription Factors
/ genetics
CRTC1/3-MAML2
NCCN Guidelines
mucoepidermoid carcinoma
salivary gland
survival analysis
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
18
07
2020
revised:
13
08
2020
accepted:
19
08
2020
pubmed:
30
8
2020
medline:
22
12
2020
entrez:
30
8
2020
Statut:
ppublish
Résumé
Mucoepidermoid carcinoma (MEC) is rare, but the most common primary malignancy of the salivary gland and not infrequent in young individuals. CRTC1/3-MAML2 fusions are frequently detected in MEC and are useful as a diagnostic biomarker. However, there has been debate as to whether the fusions have prognostic significance. In this study, we retrospectively collected 153 salivary gland MEC cases from 11 tertiary hospitals in Japan. As inclusion criteria, the MEC patients in this study had curative surgery as the initial treatment, received no preoperative treatment, and had no distant metastasis at the time of the initial surgery. The MEC diagnosis was validated by a central pathology review by five expert salivary gland pathologists. The CRTC1/3-MAML2 fusions were detected using FISH and RT-PCR. In 153 MEC cases, 90 (58.8%) were positive for CRTC1/3-MAML2 fusions. During the follow-up period, 28 (18.3%) patients showed tumor recurrence and 12 (7.8%) patients died. The presence of the fusions was associated with favorable tumor features. Of note, none of the fusion-positive patients died during the follow-up period. Statistical analysis showed that the presence of the fusions was a prognostic indicator of a better overall survival in the total and advanced-stage MEC cohorts, but not in the early-stage MEC cohort. In conclusion, CRTC1/3-MAML2 fusions are an excellent biomarker for favorable overall survival of patients with salivary gland MEC.
Identifiants
pubmed: 32860299
doi: 10.1111/cas.14632
pmc: PMC7648036
doi:
Substances chimiques
Biomarkers, Tumor
0
CRTC1 protein, human
0
CRTC3 protein, human
0
MAML2 protein, human
0
Oncogene Proteins, Fusion
0
Trans-Activators
0
Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4195-4204Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 15K08351
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 17K08746
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
EMBO J. 2005 Jul 6;24(13):2391-402
pubmed: 15961999
Am J Surg Pathol. 2019 Jul;43(7):885-897
pubmed: 31021855
Genes Chromosomes Cancer. 2006 May;45(5):470-81
pubmed: 16444749
Clin Cancer Res. 2017 Jan 1;23(1):283-288
pubmed: 27340278
Genes Chromosomes Cancer. 2007 Jul;46(7):708-15
pubmed: 17437281
Cancer Sci. 2013 Jan;104(1):85-92
pubmed: 23035786
Am J Surg Pathol. 2010 Aug;34(8):1106-21
pubmed: 20588178
Laryngoscope. 2012 Aug;122(8):1690-4
pubmed: 22833306
J Craniomaxillofac Surg. 1996 Jun;24(3):133-9
pubmed: 8842902
Head Neck. 2018 Dec;40(12):2565-2573
pubmed: 30475407
Clin Cancer Res. 2006 Jul 1;12(13):3902-7
pubmed: 16818685
Oncotarget. 2017 Apr 20;8(41):69456-69464
pubmed: 29050216
Cancer. 2012 Aug 15;118(16):3928-36
pubmed: 22180391
Exp Cell Res. 2004 Jan 1;292(1):21-8
pubmed: 14720503
J Mol Diagn. 2004 Aug;6(3):205-10
pubmed: 15269296
Nature. 2019 Mar;567(7748):305-307
pubmed: 30894741
Pediatr Blood Cancer. 2016 Jan;63(1):27-31
pubmed: 26221861
Pract Radiat Oncol. 2011;1(3):142-148
pubmed: 21857887
Asian Pac J Cancer Prev. 2014;15(19):8259-63
pubmed: 25339015
Mod Pathol. 2009 Dec;22(12):1575-81
pubmed: 19749740
Mod Pathol. 2013 Feb;26(2):213-22
pubmed: 23018873
Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):577-87
pubmed: 10524409
Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):373-82
pubmed: 18337023
Support Care Cancer. 2010 Aug;18(8):1039-60
pubmed: 20237805
JAMA Otolaryngol Head Neck Surg. 2016 Mar;142(3):234-40
pubmed: 26796488
Oral Oncol. 2017 May;68:5-8
pubmed: 28438292
Virchows Arch. 2011 Feb;458(2):133-40
pubmed: 21243374
Cancer Res. 2005 Aug 15;65(16):7137-44
pubmed: 16103063
Cancer Sci. 2020 Nov;111(11):4195-4204
pubmed: 32860299
Am J Surg Pathol. 2016 Aug;40(8):1151-3
pubmed: 27299797
J Oral Pathol Med. 2020 May;49(5):386-394
pubmed: 31661572
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 May;121(5):530-41
pubmed: 27068311
Oncogene. 2006 Oct 5;25(45):6128-32
pubmed: 16652146
Nat Genet. 2003 Feb;33(2):208-13
pubmed: 12539049
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):1007-14
pubmed: 22056067